Mesoblast Limited (MESO) News
Filter MESO News Items
MESO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MESO News Highlights
- For MESO, its 30 day story count is now at 4.
- Over the past 12 days, the trend for MESO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG, MSB and PAG are the most mentioned tickers in articles about MESO.
Latest MESO News From Around the Web
Below are the latest news stories about MESOBLAST LTD that investors may wish to consider to help them evaluate MESO as an investment opportunity.
Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory RoleNEW YORK, June 04, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce that it has appointed Dr. Philip R. Krause, a member of the Board of Directors, to a formal strategic advisory role. Dr. Krause was formerly Deputy Director of the Office of Vaccines Research and Review at the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) and is an interna |
Mesoblast Limited's (ASX:MSB) largest shareholders are individual investors with 52% ownership, institutions own 31%Key Insights Significant control over Mesoblast by individual investors implies that the general public has more power... |
Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended March 31, 2023. OPERATIONAL HIGHLIGHTS Remestemcel-L BLA filing accepted by FDA, PDUFA goal date set US Food and Drug Administration (FDA) accepted Mesoblast’s filing of the Biologics License Application (BLA) for remestemcel-L in the treatment of children wit |
Mesoblast Financial Results and Corporate Update WebcastNEW YORK, May 24, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the third quarter ended March 31, 2023. The webcast will begin at 6.30pm EDT, Thursday, May 25; 8.30am AEST, Friday, May 26, 2023. It can be accessed via: https://webcast.openbriefing.com/msb-qtr1-2023/ The archived webcast will be available on the Investor pag |
Appendix 4C Quarterly Activity ReportMesoblast Financial and Operational Highlights for Quarter Ended March 31, 2023NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2023. Financial Highlights Successful completion of a global private placement primarily to Mesoblast’s existing major US, UK, and Australian shareholders raising approximately US$40 milli |
Mesoblast Completes Private PlacementNEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has completed a global private placement primarily to Mesoblast’s existing major US, UK, and Australian shareholders raising approximately US$40 million, net of transaction costs, at A$0.85 per share. Proceeds will be used to fund: Launch and commercialization of the company’s lead product, remestemcel-L, in the treatm |
FDA Schedules Pre-License Inspection of Remestemcel-L ManufacturingBiologics License Application (BLA) Resubmission for Pediatric Acute Graft-Versus-Host Disease (SR-aGVHD) Currently Being Reviewed PDUFA Goal Date August 2, 2023 If Approved, Remestemcel-L will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and the First Therapy for Children Under 12 Years Old with SR-aGVHD NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today an |
William Blair Initiates Mesoblast Soon After Its Lead Product Goes Under FDA Review In Pediatric IndicationWilliam Blair has initiated coverage on Mesoblast Ltd (NASDAQ: MESO) with an Outperform rating and a price target of $8. Mesoblast's lead product, remestemcel-L, has shown transformative efficacy in pediatric steroid-refractory (SR) acute graft-versus-host disease (aGvHD), where no approved therapies exist for children under the age of 12. In a Phase 3 trial, 69% of pediatric SR-aGvHD patients treated with remestemcel-L were alive at day 180, and 51% were alive two years after treatment vs. 49% |
Mesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock UpMesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of children under 12 with steroid-refractory acute graft versus host disease. Stock gains on Wednesday, following the news. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're getting into the biggest pre-market stock movers traders will want to keep an eye on Wednesday with the latest news! |